Sai Life Sciences recently disclosed their Q4 FY2026 results in an earnings call. The discussion covered both financial and operational aspects of the company, as detailed in the transcript published on May 15, 2026.

HDFC Securities maintains its optimistic stance towards Sai Life Sciences, setting a price target at ₹1,280 and recommending investors to consider buying shares.

Sai Life Sciences posted impressive financial results for the fiscal year ending March 2026, with revenue surging by 31% to INR 21.5 billion and profit nearly doubling to INR 3.4 billion. Auditors have given an unmodified opinion on their findings.

Sai Life Sciences has experienced a significant increase in trading volume, breaking through consolidation levels, suggesting a bullish trend with higher highs and lows, indicating potential growth for the company.

Sai Life Sciences will announce their Q4 and FY2026 results on May 14th. The trading window is currently closed, starting from April 1st, and won't reopen until 48 hours after the results are declared.

Jefferies has given a 'Buy' recommendation for Sai Life Sciences, projecting a target price of Rs 1,300, based on the company's resilience to Middle East impacts, cost-efficient measures, and significant project wins. Sai Life's optimistic sales growth outlook (15-20% CAGR), high EBITDA margins (28-30%), absence of destocking, and visibility in late-stage pipelines are positively influencing its future prospects.

Morgan Stanley Asia Singapore Pte has purchased approximately 800,000 shares of Sai Life Sciences for ₹79.4 crores ($10.5 million USD) at a price of ₹1015.4 per share. This investment underscores Morgan Stanley's confidence in the biotech sector and Sai Life Sciences' potential growth.

Sai Life Sciences has announced the appointment of Dr. John Pavey as a senior executive, effective April 1, 2026. With over 20 years of experience in CMC, API development, and regulatory approvals at notable companies like AstraZeneca, Dr. Pavey will be replacing Dr. Dean David Edney in his new role.